It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery brings together world-class expertise to accelerate oncology drug discovery from target validation to clinical studies. Our leadership team combines experience from pharma, biotech, non-profit, and academia to deliver critical thinking and innovative solutions for your project.
Oncology candidates delivered now progressing through human clinical trials
7
Further compounds advanced into pre- clinical development
Expertise spanning traditional and emerging targets, including small molecules, degraders, and ADCs.
supporting your research
Modern cancer medicines targeting precise mutations have transformed patient outcomes, yet long-term remissions remain rare.
Our scientists work across the entire oncology discovery spectrum from target identification and lead optimization to candidate nomination and clinical positioning. Integrated teams of medicinal chemists, DMPK experts, bioscientists, and in vivo specialists collaborate to deliver cutting-edge therapeutics.
Cancer is no longer seen as a single disease. Our scientists collaborate with experts in inflammation, immunology and neurology to accelerate delivery of candidate drugs, particularly for immuno-oncology and CNS cancer projects. We design robust, tailored in vitro screening cascades supported by state-of-the-art technologies and orthogonal biophysics platforms for rapid, decision-enabling data. Our in-house Human Blood Donor Panel provides easy access to immune and inflammatory cells for immune-oncology research.
Our deep experience across oncology drug discovery and a collective knowledge base informs critical decision making. In recent years, this expertise has delivered thirteen clinical candidates in the oncology arena (spanning Phase 1-3 clinical trials), with a further seven in pre-clinical development.
Our translational oncology team designs and delivers customized preclinical studies across modalities including small molecules, biologics, ADCs, RNA/DNA therapeutics, viral and cell therapies, and radiotherapy.
We offer validated and bespoke tumour models, including xenograft, syngeneic, orthotopic and humanized systems, with capabilities spanning monotherapy, combination therapy, resistance modelling and dose/schedule optimization. These in vivo studies are supported by ex vivo platforms for detailed biomarker analysis, target engagement and immune cell profiling. In addition, we can also enrich these studies with in vivo imaging or deliver combinations in vitro and in vivo with ionizing radiation.
By integrating efficacy, pharmacokinetics, pharmacodynamics and biomarker data, we establish clear relationships that de-risk your pipeline and accelerate progress.
Our Expertise In Therapeutic Modalities
Advance your programs with Sygnature Discovery’s expertise in antibody-drug conjugates and targeted protein degradation. Our integrated teams combine deep biological insight, innovative chemistry and translational know- how to move your oncology program forward efficiently.
Allan joined Sygnature Discovery in February 2019 and serves as Vice President of Oncology Drug Discovery. With more than 25 years of experience in medicinal chemistry and drug discovery, Allan has an outstanding track record of advancing compounds into clinical trials across multiple therapeutic areas. Before joining Sygnature, he spent nine years as Head of Chemistry at the Cancer Research UK Manchester Institute Drug Discovery Unit. During his time at…
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
